Kombiglyze XR

Type: Product
Name: Kombiglyze XR
First reported Mar 31 2014 - Updated Mar 31 2014 - 1 reports

Heart-Failure Data for Alogliptin Prompt More Debate at ACC

WASHINGTON DC — The possible risk of heart failure associated with the use of the dipeptidyl peptidase-4 (DPP-4) inhibitor drugs for type 2 diabetes is once again in the spotlight, with new data reported at the American College of Cardiology 2014 Scientific ... [Published General Medicine eJournal - Mar 31 2014]
First reported Mar 14 2014 - Updated Mar 14 2014 - 1 reports

AstraZeneca diabetes pen injector OK'd

WILMINGTON, Del. -- AstraZeneca has received regulatory approval for a single-use pen injector designed to improve glycemic control in patients with type 2 diabetes â?? a disease with soaring prevalence rates.The U.S. Food and Drug Administration approved ... [Published News Leader - Mar 14 2014]
First reported Mar 12 2014 - Updated Mar 12 2014 - 1 reports

Possible Lawsuit: Saxagliptin Marketed as Onglyza and Kombiglyze XR Side Effects

Home Page >> Potential Lawsuit >> Saxagliptin marketed as Onglyza and Kombiglyze XRWere you looking for Diabetes Medication Lawsuits lawsuits?The US Food and Drug Administration (FDA) has announced it is conducting an investigation into saxagliptin ... [Published Lawyers & Settlements - Mar 12 2014]
First reported Feb 27 2014 - Updated Feb 27 2014 - 1 reports

Januvia Pancreatic Cancer Allegations Help: Resource4thePeople...

National network of lawyers continues offer of complimentary consultations to consumers seeking compensation in lawsuits alleging links between diabetes medications Januvia, Byetta, Janumet and Victoza and pancreatic cancer. http://www.resource4thepe ... [Published PRWeb - Feb 27 2014]
First reported Feb 13 2014 - Updated Feb 13 2014 - 1 reports

As Byetta Lawsuits Move Forward, Bernstein Liebhard LLP Notes New FDA...

The Firm is evaluating Byetta lawsuits and other legal claims on behalf of individuals who allegedly developed pancreatic cancer, pancreatitis, and thyroid cancer due their use of incretin mimetic medications used to treat Type 2 diabetes. As Byetta lawsuits ... [Published PRWeb - Feb 13 2014]
First reported Feb 11 2014 - Updated Feb 12 2014 - 1 reports

FDA to review possible heart risks with AstraZeneca's diabetes drug

(Reuters) - The U.S. Food and Drug Administration said it will review possible heart risks associated with AstraZeneca Plc's widely-used diabetes drug saxagliptin, marketed as Onglyza and Kombiglyze XR. The health regulator said it requested ... ... [Published Yahoo! Health News - Feb 11 2014]
First reported Feb 04 2014 - Updated Feb 05 2014 - 1 reports

AstraZeneca completes acquisition of Bristol-Myers Squibb's diabetes business

AstraZeneca has completed the acquisition of Bristol-Myers Squibb's (BMS's) interests in the companies’ diabetes alliance for $4.1bn.The acquisition gives AstraZeneca ownership of the intellectual property and global rights for the development, manufacture ... [Published Pharmaceutical Business Review - Feb 04 2014]
First reported Feb 03 2014 - Updated Feb 03 2014 - 11 reports

AstraZeneca Completes Acquisition of Diabetes Alliance Assets in the U.S. from Bristol-Myers Squibb

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca (NYSE: AZN) today announced that on February 1, 2014, it completed its acquisition of the entirety of Bristol-Myers Squibb’s interests in the companies’ diabetes alliance. The acquisition gives AstraZeneca ... [Published EON Transportation - Feb 03 2014]
First reported Jan 19 2014 - Updated Jan 19 2014 - 1 reports

Januvia Pancreatic Cancer Allegations Alert: Resource4thePeople...

National network of lawyers will resume availability for inquiries from consumers seeking compensation in lawsuits alleging links between diabetes medications Januvia, Byetta, Janumet and Victoza and pancreatic cancer. http://www.resource4thepeople.c ... [Published PRWeb - Jan 19 2014]
First reported Dec 20 2013 - Updated Dec 20 2013 - 1 reports

AstraZeneca to buy stake in Bristol-Myers Squibb's diabetes business for $4.1bn

AstraZeneca has agreed to acquire the entirety of Bristol-Myers Squibb’s interests in the companies’ diabetes alliance for $4.1bn including an initial consideration of $2.7bn on completion and up to $1.4bn in regulatory, launch and sales-related paym ... [Published Pharmaceutical Business Review - Dec 20 2013]
First reported Dec 19 2013 - Updated Dec 19 2013 - 2 reports

AstraZeneca to buy Bristol-Myers' entire global diabetes alliance assets for $4.1 billion

AstraZeneca, a global and innovation-driven biopharmaceutical business, has signed an agreement to acquire the entirety of Bristol-Myers Squibb’s interests in the companies’ diabetes alliance for an initial consideration of $2.7 billion on completion ... [Published PharmaBiz - Dec 19 2013]
First reported Dec 19 2013 - Updated Dec 19 2013 - 1 reports

Byetta Pancreatic Cancer Allegations Attorneys: Resource4thePeople...

National network of lawyers will continue offer of these consultations through Christmas and New Year’s Day. Allegations involve links between diabetes medications Byetta, Januvia, Janumet and Victoza and pancreatic cancers. http://www.resource4thepe ... [Published PRWeb - Dec 19 2013]

Quotes

"The patient I'm thinking I wouldn't start on a DPP-4 inhibitor is someone who has current, established heart failure. If they had something 10 years ago"
AstraZeneca CEO Pascal Soriot said, "Under a single leadership, we will maximise the potential of our innovative portfolio of non-insulin anti-diabetic medicines, bringing fresh momentum to our growth ambitions for this franchise." On completion of the deal, AstraZeneca paid BMS $2.7bn of initial consideration and has also agreed to pay upup to $1...

More Content

All (29) | News (17) | Reports (0) | Blogs (12) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Heart-Failure Data for Alogliptin Prompt More D... [Published General Medicine eJournal - Mar 31 2014]
AstraZeneca diabetes pen injector OK'd [Published News Leader - Mar 14 2014]
Possible Lawsuit: Saxagliptin Marketed as Ongly... [Published Lawyers & Settlements - Mar 12 2014]
Januvia Pancreatic Cancer Allegations Help: Res... [Published PRWeb - Feb 27 2014]
As Byetta Lawsuits Move Forward, Bernstein Lieb... [Published PRWeb - Feb 13 2014]
FDA to review possible heart risks with AstraZe... [Published Yahoo! Health News - Feb 11 2014]
AstraZeneca completes acquisition of Bristol-My... [Published Pharmaceutical Business Review - Feb 04 2014]
AstraZeneca Completes Acquisition of Diabetes A... [Published EON Transportation - Feb 03 2014]
AstraZeneca Completes Acquisition of Diabetes A... [Published EON Environment - Feb 03 2014]
AstraZeneca Completes Acquisition of Diabetes A... [Published EON Retail - Feb 03 2014]
AstraZeneca Completes Acquisition of Diabetes A... [Published EON Manufacturing - Feb 03 2014]
AstraZeneca Completes Acquisition of Diabetes A... [Published EON Science - Feb 03 2014]
AstraZeneca Completes Acquisition of Diabetes A... [Published EON: Enhanced Online News - Feb 03 2014]
AstraZeneca Completes Acquisition of Diabetes A... [Published EON Energy - Feb 03 2014]
AstraZeneca Completes Acquisition of Diabetes A... [Published EON Communications - Feb 03 2014]
AstraZeneca Completes Acquisition of Diabetes A... [Published EON Consumer - Feb 03 2014]
AstraZeneca Completes Acquisition of Diabetes A... [Published EON Business - Feb 03 2014]
AstraZeneca Completes Acquisition of Diabetes A... [Published Business Wire Health News - Feb 03 2014]
Januvia Pancreatic Cancer Allegations Alert: Re... [Published PRWeb - Jan 19 2014]
AstraZeneca to buy stake in Bristol-Myers Squib... [Published Pharmaceutical Business Review - Dec 20 2013]
AstraZeneca to buy Bristol-Myers' entire global... [Published PharmaBiz - Dec 19 2013]
Byetta Pancreatic Cancer Allegations Attorneys:... [Published PRWeb - Dec 19 2013]
AZ to acquire BMS share of diabetes assets [Published TrustNet - Dec 19 2013]
Byetta Pancreatic Cancer Allegation Attorneys: ... [Published PRWeb - Nov 27 2013]
Byetta Pancreatic Cancer Allegations Lawyers: R... [Published PRWeb - Nov 05 2013]
Latest Januvia Lawsuits Alleging Pancreatic Can... [Published PRWeb - Oct 14 2013]
Byetta Lawsuits Alleging Pancreatic Cancer Help... [Published PRWeb - Sep 13 2013]
Half Yearly Pipeline Update [Published TrustNet - Aug 01 2013]
New Byetta Pancreatic Cancer Allegation Lawsuit... [Published PRWeb - Jul 24 2013]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
FDA to review possible heart risks with AstraZe... [Published Yahoo! Health News - Feb 11 2014]
(Reuters) - The U.S. Food and Drug Administration said it will review possible heart risks associated with AstraZeneca Plc's widely-used diabetes drug saxagliptin, marketed as Onglyza and Kombiglyze XR. The health regulator said it requested ... ...
AstraZeneca Completes Acquisition of Diabetes A... [Published EON Transportation - Feb 03 2014]
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca (NYSE: AZN) today announced that on February 1, 2014, it completed its acquisition of the entirety of Bristol-Myers Squibb’s interests in the companies’ diabetes alliance. The acquisition gives AstraZeneca ...
AstraZeneca Completes Acquisition of Diabetes A... [Published EON Environment - Feb 03 2014]
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca (NYSE: AZN) today announced that on February 1, 2014, it completed its acquisition of the entirety of Bristol-Myers Squibb’s interests in the companies’ diabetes alliance. The acquisition gives AstraZeneca ...
AstraZeneca Completes Acquisition of Diabetes A... [Published EON Retail - Feb 03 2014]
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca (NYSE: AZN) today announced that on February 1, 2014, it completed its acquisition of the entirety of Bristol-Myers Squibb’s interests in the companies’ diabetes alliance. The acquisition gives AstraZeneca ...
AstraZeneca Completes Acquisition of Diabetes A... [Published EON Manufacturing - Feb 03 2014]
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca (NYSE: AZN) today announced that on February 1, 2014, it completed its acquisition of the entirety of Bristol-Myers Squibb’s interests in the companies’ diabetes alliance. The acquisition gives AstraZeneca ...
1 2 3
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.